Publications 2025

Kannen V, Olafsen NE, Das S, Giuliana P, Izzati FN, Choksi H, Åhrling SS, Cappello P, Teino I, Maimets T, Jaudzems K, Gulbinas A, Dambrauskas Z, Edgar LJ, Grant DM, Matthews J (2025)
Loss of aryl hydrocarbon receptor reduces pancreatic tumor growth by increasing immune cell infiltration
Biochem Pharmacol, 236, 116872
DOI 10.1016/j.bcp.2025.116872, PubMed 40090596

Kannen V, Rasmussen M, Das S, Giuliana P, Izzati FN, Choksi H, Erlingsson LAM, Olafsen NE, Åhrling SS, Cappello P, Teino I, Maimets T, Jaudzems K, Gulbinas A, Dambrauskas Z, Edgar LJ, Grant DM, Matthews J (2025)
Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration
Front Immunol, 15, 1513595
DOI 10.3389/fimmu.2024.1513595, PubMed 39867896

Olafsen NE, Åhrling SS, Rasmussen M, Erlingsson LAM, Granly EN, Takaoka A, Matthews J (2025)
PARP7 and aryl hydrocarbon receptor differentially regulate mammary cancer cell proliferation and STING-induced type I interferon signalling
Cell Oncol (Dordr), 49 (1), 3
DOI 10.1007/s13402-025-01150-w, PubMed 41432900

Publications 2024

Bobrovs R, Terentjeva S, Olafsen NE, Dambrauskas Z, Gulbinas A, Maimets T, Teino I, Jirgensons A, Matthews J, Jaudzems K (2024)
Discovery and optimisation of pyrazolo[1,5-a]pyrimidines as aryl hydrocarbon receptor antagonists
RSC Med Chem, 15 (10), 3477-84 (in press)
DOI 10.1039/d4md00266k, PubMed 39246744

Olafsen NE, Das S, Gorrini C, Matthews J (2024)
Long-term exposure to BAY2416964 reduces proliferation, migration and recapitulates transcriptional changes induced by AHR loss in PyMT-induced mammary tumor cells
Front Oncol, 14, 1466658
DOI 10.3389/fonc.2024.1466658, PubMed 39450255

Olafsen NE, Das S, Gorrini C, Matthews J (2024)
Corrigendum: Long-term exposure to BAY2416964 reduces proliferation, migration and recapitulates transcriptional changes induced by AHR loss in PyMT-induced mammary tumor cells
Front Oncol, 14, 1516633
DOI 10.3389/fonc.2024.1516633, PubMed 39628995

Publications 2023

Rasmussen M, Alvik K, Kannen V, Olafsen NE, Erlingsson LAM, Grimaldi G, Takaoka A, Grant DM, Matthews J (2023)
Loss of PARP7 Increases Type I Interferon Signaling in EO771 Breast Cancer Cells and Prevents Mammary Tumor Growth by Increasing Antitumor Immunity
Cancers (Basel), 15 (14)
DOI 10.3390/cancers15143689, PubMed 37509350

Publications 2022

Li BB, Scott EY, Olafsen NE, Matthews J, Wheeler AR (2022)
Analysis of the effects of aryl hydrocarbon receptor expression on cancer cell invasion via three-dimensional microfluidic invasion assays
Lab Chip, 22 (2), 313-325
DOI 10.1039/d1lc00854d, PubMed 34904612

Sanderson DJ, Rodriguez KM, Bejan DS, Olafsen NE, Bohn ID, Kojic A, Sundalam S, Siordia IR, Duell AK, Deng N, Schultz C, Grant DM, Matthews J, Cohen MS (2022)
Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling
Cell Chem Biol, 30 (1), 43-54.e8
DOI 10.1016/j.chembiol.2022.11.012, PubMed 36529140

Publications 2021

Hutin D, Long AS, Sugamori K, Shao P, Singh SK, Rasmussen M, Olafsen NE, Pettersen S, Grimaldi G, Grant DM, Matthews J (2021)
2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality
Toxicol Sci, 183 (1), 154-169
DOI 10.1093/toxsci/kfab075, PubMed 34129049

Rasmussen M, Tan S, Somisetty VS, Hutin D, Olafsen NE, Moen A, Anonsen JH, Grant DM, Matthews J (2021)
PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells
Cells, 10 (3)
DOI 10.3390/cells10030623, PubMed 33799807